MS4A1 and B-cell non-Hodgkin lymphoma: It is indicated for use as a single agent for relapsed/refractory, low‐grade/ follicular CD20‐positive, B‐cell NHL, and in patients with non‐progressing, low‐grade, CD20‐positive, B‐cell NHL after first‐line cyclophosphamide, vincristine, and prednisolone (CVP) chemotherapy.